Certain patients with germ cell cancer should receive life-long follow-up
the ONA take:
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death, and therefore should be candidates for life-long follow-up care, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, researchers identified 268 patients with germ cell cancer who received more than one line of treatment for disseminated disease from the Danish Testicular Cancer database to evaluate late toxicity and survival.
Results showed that just more than half of patients died from germ cell cancer. The remaining patients had an increased risk for developing a second cancer, major cardiovascular disease, pulmonary disease, gastrointestinal disease, renal impairment, neurologic disorders, and death from other causes compared with patients who only underwent orchiectomy.
Researchers found that increasing age may contribute to treatment failure after second-line treatment in these patients.
Patients with disseminated germ cell cancer who survive after more than one line of treatment have an increased risk for late toxicity and death.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|